These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31359508)

  • 21. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
    Lai H; Gardner V; Vetter J; Andriole GL
    BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urethral dilatation: Is there any benefit over cystoscopy and distension? A randomized trial in women with overactive bladder symptoms.
    Basu M; Khullar V; Duckett J
    Neurourol Urodyn; 2014 Mar; 33(3):283-8. PubMed ID: 23636866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overactive bladder and urgency urinary incontinence in men undergoing artificial urinary sphincter placement.
    Jahromi MS; Engle K; Furlong D; Guevara Méndez A; Gomez CS
    Neurourol Urodyn; 2020 Jun; 39(5):1489-1493. PubMed ID: 32339308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective bladder denervation for overactive bladder (OAB) syndrome: From concept to healing outcomes using the ovine model.
    Fugett J; Phillips L; Tobin E; Whitbrook E; Bennett H; Shrout J; Coad JE
    Neurourol Urodyn; 2018 Sep; 37(7):2097-2105. PubMed ID: 29603776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.
    Abdel-Fattah M; Chapple C; Guerrero K; Dixon S; Cotterill N; Ward K; Hashim H; Monga A; Brown K; Drake MJ; Gammie A; Mostafa A; Bladder Health UK; Breeman S; Cooper D; MacLennan G; Norrie J
    Trials; 2021 Oct; 22(1):745. PubMed ID: 34702331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
    Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
    Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
    Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
    J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
    Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
    J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel leadless, miniature implantable Tibial Nerve Neuromodulation System for the management of overactive bladder complaints.
    Heesakkers JPFA; Digesu GA; van Breda J; Van Kerrebroeck P; Elneil S
    Neurourol Urodyn; 2018 Mar; 37(3):1060-1067. PubMed ID: 28892221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
    Amundsen CL; Richter HE; Menefee SA; Komesu YM; Arya LA; Gregory WT; Myers DL; Zyczynski HM; Vasavada S; Nolen TL; Wallace D; Meikle SF
    JAMA; 2016 Oct; 316(13):1366-1374. PubMed ID: 27701661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective assessment of overactive bladder symptoms in a cohort of elderly women who underwent transvaginal surgery for advanced pelvic organ prolapse.
    Foster RT; Barber MD; Parasio MF; Walters MD; Weidner AC; Amundsen CL
    Am J Obstet Gynecol; 2007 Jul; 197(1):82.e1-4. PubMed ID: 17618768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of transobturator tape on overactive bladder symptoms and urge urinary incontinence in women with mixed urinary incontinence.
    Tahseen S; Reid P
    Obstet Gynecol; 2009 Mar; 113(3):617-623. PubMed ID: 19300325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS).
    Martin-Garcia M; Crampton J
    Physiotherapy; 2019 Dec; 105(4):469-475. PubMed ID: 30862384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.
    Coyne KS; Sexton CC; Kopp ZS; Ebel-Bitoun C; Milsom I; Chapple C
    BJU Int; 2011 Nov; 108(9):1459-71. PubMed ID: 21371240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of baseline severity of lower urinary tract symptoms with the success conservative therapy for urinary incontinence in women.
    Obloza A; Teo R; Marriott E; Parker G; Tincello D
    Int Urogynecol J; 2019 May; 30(5):705-710. PubMed ID: 30306193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.